Hiroko Masuda

3.9k total citations · 2 hit papers
73 papers, 2.9k citations indexed

About

Hiroko Masuda is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Hiroko Masuda has authored 73 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 28 papers in Cancer Research and 17 papers in Molecular Biology. Recurrent topics in Hiroko Masuda's work include Breast Cancer Treatment Studies (19 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Cells and Metastasis (7 papers). Hiroko Masuda is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Cells and Metastasis (7 papers). Hiroko Masuda collaborates with scholars based in Japan, United States and Belgium. Hiroko Masuda's co-authors include Naoto T. Ueno, Gabriel N. Hortobágyi, Hiroyoshi Doihara, Chandra Bartholomeusz, Dongwei Zhang, Vicente Valero, W. Fraser Symmans, Ana M. González-Angulo, K. Nagata and Kazunori Hirayoshi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Hiroko Masuda

72 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of epidermal growth factor receptor in breast cancer

2012 602 citations Hiroko Masuda, Hiroyoshi Doihara et al. profile →
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

2013 525 citations Hiroko Masuda, Keith Baggerly et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hiroko Masuda Japan	26	1.3k	1.1k	1.1k	489	249	73	2.9k
Karen Page United Kingdom	31	774 0.6×	1.7k 1.6×	1.1k 1.1×	386 0.8×	276 1.1×	64	2.8k
Kun‐Tu Yeh Taiwan	35	783 0.6×	2.0k 1.8×	751 0.7×	337 0.7×	286 1.1×	151	3.7k
Hyun Goo Woo South Korea	32	665 0.5×	1.7k 1.5×	931 0.9×	410 0.8×	185 0.7×	106	3.1k
Junran Zhang United States	33	1.2k 0.9×	2.9k 2.6×	960 0.9×	660 1.3×	208 0.8×	71	3.9k
Shunbin Xiong United States	26	1.2k 0.9×	1.6k 1.5×	619 0.6×	282 0.6×	117 0.5×	47	2.5k
Yanan Yang China	29	668 0.5×	1.8k 1.7×	736 0.7×	364 0.7×	141 0.6×	100	2.8k
Zhongmin Guo United States	25	762 0.6×	1.7k 1.6×	598 0.6×	259 0.5×	224 0.9×	39	2.6k
Kai Stoeber United Kingdom	33	1.1k 0.8×	2.3k 2.1×	746 0.7×	488 1.0×	302 1.2×	63	3.8k
Hong Yin China	32	531 0.4×	1.8k 1.7×	880 0.8×	236 0.5×	258 1.0×	90	3.6k

Countries citing papers authored by Hiroko Masuda

Since Specialization

Citations

This map shows the geographic impact of Hiroko Masuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Masuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Masuda more than expected).

Fields of papers citing papers by Hiroko Masuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Masuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Masuda. The network helps show where Hiroko Masuda may publish in the future.

Co-authorship network of co-authors of Hiroko Masuda

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Masuda. A scholar is included among the top collaborators of Hiroko Masuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Masuda. Hiroko Masuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshinami, Tetsuhiro, Shigenori E. Nagai, Masaya Hattori, et al.. (2024). Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer. 31(4). 621–632. 2 indexed citations

Masuda, Hiroko, Yuko Tanabe, Koji Matsumoto, et al.. (2023). Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). The Breast. 71. 22–28. 13 indexed citations

Kuwayama, Takashi, et al.. (2023). Clinical significance of blood endocan level in breast cancer patients. The Showa University Journal of Medical Sciences. 35(2). 98–102. 1 indexed citations

Liu, Lei, Junji Tsurutani, Sadako Akashi‐Tanaka, et al.. (2020). BRCAness as a prognostic indicator in patients with early breast cancer. Scientific Reports. 10(1). 21173–21173. 16 indexed citations

Funakoshi, Yohei, Ying Wang, Takashi Semba, et al.. (2019). Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS ONE. 14(9). e0222336–e0222336. 17 indexed citations

Akashi‐Tanaka, Sadako, Chiho Watanabe, Hiroko Masuda, et al.. (2017). Diagnostic performance of dedicated breast PET scanner with a ring detector. Annals of Oncology. 28. v452–v452. 1 indexed citations

Kai, Kazuharu, Kimie Kondo, Xiaoping Wang, et al.. (2015). Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Molecular Cancer Therapeutics. 14(12). 2687–2699. 17 indexed citations

Kogawa, Takahiro, Tamer M. Fouad, Diane D. Liu, et al.. (2015). High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. The Oncologist. 21(1). 21–27. 23 indexed citations

Honda, Takashi, Masatoshi Ishigami, Hiroko Masuda, et al.. (2014). Effect of peginterferon alfa‐2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology. 30(2). 321–328. 7 indexed citations

10.

Masuda, Hiroko, Keith Baggerly, Ying Wang, et al.. (2013). Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clinical Cancer Research. 19(19). 5533–5540. 525 indexed citations breakdown →

11.

Bertucci, François, Naoto T. Ueno, Pascal Finetti, et al.. (2013). Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology. 25(2). 358–365. 77 indexed citations

12.

Takatsuru, Yusuke, Kei Eto, Ryosuke Kaneko, et al.. (2013). Critical Role of the Astrocyte for Functional Remodeling in Contralateral Hemisphere of Somatosensory Cortex after Stroke. Journal of Neuroscience. 33(11). 4683–4692. 50 indexed citations

13.

Muraoka, Takayuki, Kazunori Tsukuda, Shinichi Toyooka, et al.. (2011). Ileal perforation induced by acute radiation injury under gefitinib treatment. International Journal of Clinical Oncology. 16(6). 774–777. 10 indexed citations

14.

Masuda, Hiroko, Fumio Otsuka, Yoshinori Matsumoto, et al.. (2011). Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation. Molecular and Cellular Endocrinology. 343(1-2). 7–17. 13 indexed citations

15.

Masuda, Hiroko, Norikazu Masuda, Yoshinori Kodama, et al.. (2010). Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemotherapy and Pharmacology. 67(4). 911–917. 55 indexed citations

16.

Tanaka, Kenzo, et al.. (2006). Size-related changes in photosynthesis and leaf characteristics in Sabina vulgaris Ant in the Mu-us Desert, Inner Mongolia, China. Journal of the Japanese Society of Revegetation Technology. 31(4). 436–440. 2 indexed citations

17.

Natsume, Hiroko, Shigekazu Sasaki, Masatoshi Kitagawa, et al.. (2003). β-Catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochemical and Biophysical Research Communications. 309(2). 408–413. 42 indexed citations

18.

Masuda, Hiroko, Nobuko Hosokawa, & Kazuhiro Nagata. (1998). Expression and localization of collagen-binding stress protein Hsp47 in mouse embryo development: comparison with types I and II collagen. Cell Stress and Chaperones. 3(4). 256–256. 40 indexed citations

19.

Tanaka, Yasuyuki, Kappei Kobayashi, Masakazu Kita, et al.. (1996). Expression of 47 kDa Heat Shock Protein (HSP47) during Development of Mouse Cornea. Experimental Eye Research. 63(4). 383–393. 16 indexed citations

20.

Masuda, Hiroko, et al.. (1994). Visual pigments in the pineal complex of the Japanese quail, Japanese grass lizard and bullfrog: Immunocytochemistry and HPLC analysis. Tissue and Cell. 26(1). 101–113. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact